

※On November 17, 2023, we announced corrections of timing of the operation launch of 2nd sterile formulation building.



Press Release

November 16, 2023

Press Release

TOWA PHARMACEUTICAL CO., LTD.

Construction Works Aimed at Increasing the Yamagata Plant's Production Capacity Completed

—Establishing a system of three plants in Japan producing a total of 17.5 billion tablets a year—

TOWA PHARMACEUTICAL CO., LTD. (Headquarters: Kadoma, Osaka; President and Representative Director: Itsuro Yoshida; hereinafter, the “Company”) has announced that construction works aimed at increasing the production capacity of the Yamagata Plant have been completed, whereby the Company has established a system for increasing the total production capacity of its plants to 17.5 billion tablets a year.

The construction works were carried out from 2021 in order to increase the annual production capacity of the Yamagata Plant from 6.5 billion tablets to 10.0 billion tablets. Through this capacity increase, the Company aims not only to fulfill its responsibility for maintaining a stable supply of products as a generic pharmaceutical manufacturer but also to get ready to fulfill growing demand in anticipation of a future increase in its market share. The completed construction works have allowed the Company to expand its annual total production capacity to 17.5 billion tablets: 2.5 billion at the Osaka Plant, 5.0 billion at the Okayama Plant, and 10.0 billion at the Yamagata Plant.

The Company will continue its efforts to maintain a stable supply of products and provide the high-quality generic pharmaceuticals that patients and medical professionals need.



■ Overview of newly constructed buildings at the Yamagata Plant

Building name	3rd solid formulation building	2nd sterile formulation building
Total floor area	29,574 m ²	17,160 m ²
Ground coverage area	6,276 m ²	4,379 m ²
Structure	Five-story steel-frame building	Four-story steel-frame building
Annual production capacity	3.5 billion tablets	5.5 million vials
Total amount of investment	54.9 billion yen (28.4 billion yen in the buildings and 26.5 billion yen in equipment)	
Timing of the operation launch	Scheduled for April 2024	<u>Scheduled for April 2025</u>

[Inquiries]

Public Relations and Investor Relations Department, Towa Pharmaceutical Co., Ltd.

2-11 Shinbashi-cho, Kadoma, Osaka 571-8580, Japan

Tel: +81-6-6900-9102 / Fax: +81-6-7177-4960 / Email: kouhou@towayakuhin.co.jp

1 / 1